This webinar introduces key updates in acute ischemic stroke management, focusing on how modern decision‑making integrates time‑sensitive evaluation, advanced imaging, and AI‑supported tools. It also reviews the expanded…
Pompe disease is a rare, life-threatening genetic disorder caused by GAA enzyme deficiency, leading to glycogen buildup and muscle cell destruction. It presents on a spectrum, from infantile-onset…
The FDA has expanded indications for methylphenidate (Concerta) extended-release tablets to include adults aged 18 to 65 with ADHD. For more information visit: FDA Sponsored by The Doctor’s…
According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in…
The non-steroidal, anti-inflammatory drugs celecoxib and naproxen sodium do not improve cognitive function, ADAPT trial data indicate. From our partners at VerusMed: VerusMed.com Sponsored by The Doctor’s Channel
As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at…
New research indicates that treatment with the investigational anti-amyloid drug Tarenflurbil appears to be well-tolerated in patients with mild to moderate Alzheimer’s disease and may exert a dose-related…
In a recent study, fluoxetine (Prozac) decreased progression of relapsing-remitting MS in a small placebo-controlled study, but the effect lasted only a few months. References and Resources Mostert…
A tablet that combines sumatriptan and naproxen (Treximet) has been approved by the FDA for treatment of migraine with and without aura. References and Resources FDA Sponsored by…
Greg Foltz, MD, Director, Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, discusses current treatments for brain cancer. References and Resources Schönekaes K, Mücke R,…
Rituximab failed to meet the primary endpoint of stemming the progression of primary-progressive multiple sclerosis (PPMS) in a Phase II/III trial. From Our Partners at VerusMed verusmed.com Sponsored…
At the American Academy of Neurology meeting, researchers gave final results of the phase III PRECISE trial of glatiramer acetate (Copaxone), which delayed the onset of clinically confirmed…
